Cantor Fitzgerald Comments on KALV FY2026 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the specialty pharmaceutical company will post earnings of ($3.62) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01.

A number of other research analysts have also issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. TD Cowen started coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target on the stock. Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.00.

KalVista Pharmaceuticals Stock Down 2.2 %

NASDAQ:KALV opened at $8.56 on Wednesday. The company’s 50 day moving average is $8.92 and its 200-day moving average is $11.09. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.88. The firm has a market cap of $423.04 million, a price-to-earnings ratio of -2.35 and a beta of 0.86.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 0.5% in the 3rd quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock worth $48,775,000 after buying an additional 20,000 shares in the last quarter. Vestal Point Capital LP grew its position in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after acquiring an additional 1,700,000 shares during the period. Great Point Partners LLC acquired a new position in KalVista Pharmaceuticals during the second quarter worth $15,768,000. State Street Corp lifted its holdings in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the period. Finally, Emerald Advisers LLC boosted its stake in shares of KalVista Pharmaceuticals by 29.8% in the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after purchasing an additional 192,091 shares in the last quarter.

Insider Activity

In other news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,291 shares of company stock valued at $304,086. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).